Evidence map›Paper›PMID 27242518›Full record

ArticleFrontiers in aging neuroscience2016

Glycines from the APP GXXXG/GXXXA Transmembrane Motifs Promote Formation of Pathogenic Aβ Oligomers in Cells.

Marie Decock, Serena Stanga, Jean-Noël Octave, Ilse Dewachter, Steven O Smith, Stefan N Constantinescu, Pascal Kienlen-Campard

Open access · goldAbstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Marie DecockCEMO-Alzheimer Dementia, Institute of Neuroscience, Université Catholique de Louvain Brussels, Belgium.
Serena StangaCEMO-Alzheimer Dementia, Institute of Neuroscience, Université Catholique de Louvain Brussels, Belgium.
Jean-Noël OctaveCEMO-Alzheimer Dementia, Institute of Neuroscience, Université Catholique de Louvain Brussels, Belgium.
Ilse DewachterCEMO-Alzheimer Dementia, Institute of Neuroscience, Université Catholique de Louvain Brussels, Belgium.
Steven O SmithDepartment of Biochemistry and Cell Biology, Stony Brook University, Stony Brook NY, USA.
Stefan N ConstantinescuLudwig Institute for Cancer Research - de Duve Institute, Université Catholique de Louvain Brussels, Belgium.
Pascal Kienlen-CampardCEMO-Alzheimer Dementia, Institute of Neuroscience, Université Catholique de Louvain Brussels, Belgium.
UCLouvain · BEde Duve Institute · BEStony Brook University · US

Funding

Structure-inhibition of amyloid oligomers and fibrilsR01AG027317 · NIA · STATE UNIVERSITY NEW YORK STONY BROOK · PI SMITH, STEVEN OWEN · 2006 to 2015
$3.0M
NIA NIH HHS R01 AG027317
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative disorder characterized by progressive cognitive decline leading to dementia. The amyloid precursor protein (APP) is a ubiquitous type I transmembrane (TM) protein sequentially processed to generate the β-amyloid peptide (Aβ), the major constituent of senile plaques that are typical AD lesions. There is a growing body of evidence that soluble Aβ oligomers correlate with clinical symptoms associated with the disease. The Aβ sequence begins in the extracellular juxtamembrane region of APP and includes roughly half of the TM domain. This region contains GXXXG and GXXXA motifs, which are critical for both TM protein interactions and fibrillogenic properties of peptides derived from TM α-helices. Glycine-to-leucine mutations of these motifs were previously shown to affect APP processing and Aβ production in cells. However, the detailed contribution of these motifs to APP dimerization, their relation to processing, and the conformational changes they can induce within Aβ species remains undefined. Here, we describe highly resistant Aβ42 oligomers that are produced in cellular membrane compartments. They are formed in cells by processing of the APP amyloidogenic C-terminal fragment (C99), or by direct expression of a peptide corresponding to Aβ42, but not to Aβ40. By a point-mutation approach, we demonstrate that glycine-to-leucine mutations in the G(29)XXXG(33) and G(38)XXXA(42) motifs dramatically affect the Aβ oligomerization process. G33 and G38 in these motifs are specifically involved in Aβ oligomerization; the G33L mutation strongly promotes oligomerization, while G38L blocks it with a dominant effect on G33 residue modification. Finally, we report that the secreted Aβ42 oligomers display pathological properties consistent with their suggested role in AD, but do not induce toxicity in survival assays with neuronal cells. Exposure of neurons to these Aβ42 oligomers dramatically affects neuronal differentiation and, consequently, neuronal network maturation.

Indexed as

Alzheimer’s diseaseamyloid precursor proteinbeta-amyloid peptideGXXXG motifsneuronal differentiationoligomers

Identifiers

PMID27242518
PMCPMC4861705
OpenAlexW2346222079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.